Affinage

Showing LMAN2LVIPL is a alias.

LMAN2L

VIP36-like protein · UniProt Q9H0V9

Length
348 aa
Mass
39.7 kDa
Annotated
2026-06-10
11 papers in source corpus 7 papers cited in narrative 9 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

LMAN2L (VIPL) is a Ca2+-dependent L-type lectin and ER-resident membrane protein that functions as a cargo recognition factor for high-mannose glycoproteins in the early secretory pathway (PMID:17621594, PMID:18025080). Unlike the cycling lectins ERGIC-53 and VIP36, LMAN2L is a non-cycling ER resident retained by a cytoplasmic di-arginine (RKR/KRFY) signal; mutation of this motif sends the protein to the cell surface (PMID:12609988, PMID:12878160). Its carbohydrate recognition domain selectively binds the deglucosylated Manα1-2Manα1-2Man trimannose of the D1 branch of high-mannose N-glycans in a Ca2+-dependent manner, with binding favored at the neutral pH of the ER lumen and abolished by glucosylation of the outer mannose (PMID:17621594, PMID:18025080). Functionally, LMAN2L supports ER export and trafficking of glycoproteins, including integrin alpha-6 (ITGA6), and is required for STING translocation from the ER to the Golgi upon activation, with its loss diminishing HCMV-induced type I interferon and ISG responses without affecting STING dimerization or TBK1 recruitment (PMID:12878160, PMID:38687323, PMID:42149942). LMAN2L is itself a target of HCMV-driven ERAD: viral pUS2 recruits the host E3 ligases TRC8 or RNF139 with the E2 enzyme UBE2G2 to direct LMAN2L for proteasomal degradation (PMID:38687323, PMID:42149942). A frameshift mutation eliminating the ER retention signal causes plasma-membrane mislocalization and links LMAN2L to brain development (PMID:31020005).

Mechanistic history

Synthesis pass · year-by-year structured walk · 6 steps
  1. 2003 High

    Established that LMAN2L is a distinct, non-cycling ER-resident lectin whose localization depends on a cytoplasmic di-arginine retrieval signal, distinguishing it from cycling family members ERGIC-53 and VIP36.

    Evidence Mutagenesis of the cytoplasmic RKR/KRFY motif with subcellular localization and pulse-chase analysis in cultured cells, replicated by two labs

    PMID:12609988 PMID:12878160

    Open questions at the time
    • Does not identify the retrograde transport machinery reading the di-arginine signal
    • Does not define the physiological glycoprotein cargo at this stage
  2. 2003 Medium

    Implicated LMAN2L in early-secretory-pathway regulation and glycoprotein ER export, addressing what cellular process it serves.

    Evidence Overexpression redistributing ERGIC-53 to the ER, plus siRNA knockdown slowing secretion of two glycoproteins in cultured cells

    PMID:12609988 PMID:12878160

    Open questions at the time
    • Secreted glycoprotein cargoes identified only by molecular weight, not molecular identity
    • Mechanistic relationship to ERGIC-53 not resolved
  3. 2007 High

    Defined the molecular basis of cargo recognition, showing LMAN2L is a Ca2+-dependent lectin selective for the deglucosylated D1-branch trimannose of high-mannose N-glycans, with pH and glucosylation gating binding.

    Evidence Recombinant soluble LMAN2L analyzed by flow cytometry, SPR, frontal affinity chromatography with a pyridylaminated sugar library, and structure-based CRD mutagenesis

    PMID:17621594 PMID:18025080

    Open questions at the time
    • In vitro glycan binding not directly linked to specific endogenous cargo in cells
    • Crystal structure of LMAN2L itself not reported
  4. 2019 Medium

    Connected the ER retention signal to organismal physiology, showing loss of retention causes plasma-membrane mislocalization and links LMAN2L to brain development.

    Evidence Genetic analysis of a dominant frameshift mutation (c.1073delT) with protein localization assay

    PMID:31020005

    Open questions at the time
    • Cellular mechanism connecting mislocalization to neurodevelopmental phenotype unresolved
    • Single study
  5. 2024 Medium

    Identified a specific endogenous trafficking cargo and revealed LMAN2L as a viral ERAD target, showing LMAN2L is required for cell-surface ITGA6 and is degraded by HCMV pUS2 via TRC8.

    Evidence Plasma-membrane proteomic profiling, pUS2/TRC8 knockdown and overexpression, and co-immunoprecipitation

    PMID:38687323

    Open questions at the time
    • Direct lectin-glycan interaction with ITGA6 not biochemically demonstrated
    • Single study with limited mechanistic depth
  6. 2026 Medium

    Placed LMAN2L in innate antiviral signaling, showing it physically interacts with STING and is essential for STING ER-to-Golgi translocation and downstream interferon responses, and is degraded via pUS2-RNF139-UBE2G2 ERAD.

    Evidence Reciprocal co-immunoprecipitation, co-localization, LMAN2L knockout with STING translocation and IFN/ISG readouts, and E3/E2 identification

    PMID:42149942

    Open questions at the time
    • Whether STING engagement is glycan-dependent via the CRD is not established
    • Single-lab study
    • Distinction between TRC8 and RNF139 as the operative ligase across contexts unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unknown how LMAN2L's lectin glycan-recognition activity mechanistically couples to selection of specific cargoes such as ITGA6 and STING and to its neurodevelopmental role.
  • No structure of LMAN2L CRD bound to physiological cargo
  • Recruitment/retrieval machinery for the di-arginine signal not identified
  • Glycan-dependence of STING and ITGA6 handling untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Localization
GO:0005783 endoplasmic reticulum 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-9609507 Protein localization 2 R-HSA-168256 Immune System 1

Evidence

Reading pass · 9 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 VIPL (LMAN2L) is a non-cycling resident protein of the ER, unlike VIP36 and ERGIC-53 which cycle in the early secretory pathway. ER retention of VIPL involves a di-arginine (RKR) signal in its cytoplasmic tail, as demonstrated by mutagenesis experiments. Mutagenesis, subcellular localization (cell culture expression), pulse-chase analysis The Journal of biological chemistry High 12609988 12878160
2003 Overexpression of VIPL (LMAN2L) redistributed ERGIC-53 to the ER without affecting the cycling of the KDEL-receptor or overall early secretory pathway morphology, suggesting VIPL functions as a regulator of ERGIC-53. Overexpression in cell culture with immunofluorescence localization of ERGIC-53 The Journal of biological chemistry Medium 12609988
2003 Knockdown of VIPL (LMAN2L) mRNA by siRNA significantly slowed the secretion of two glycoproteins (Mr 35 and 250 kDa), supporting a role for VIPL as an ER export receptor for glycoproteins. siRNA knockdown with secretion assay (pulse-chase/medium collection) Experimental cell research Medium 12878160
2003 Mutating the retrograde transport signal KR to AA in the VIPL (LMAN2L) cytoplasmic tail (KRFY motif) resulted in transport of VIPL to the cell surface, confirming that the KR motif mediates ER/ERGIC retrieval. Site-directed mutagenesis with subcellular localization assay (immunofluorescence, surface expression) Experimental cell research High 12609988 12878160
2007 VIPL (LMAN2L) has sugar-binding activity specific for high-mannose-type N-glycans, preferentially recognizing the Manα1-2Manα1-2Man sequence (deglucosylated trimannose in the D1 branch). Glucosylation of the outer mannose residue blocks binding. Sugar-binding activity is stronger at neutral pH (ER lumen pH) than under acidic conditions. Flow cytometry with recombinant soluble VIPL, surface plasmon resonance, competition with high-mannose N-glycans, endoglycosidase H treatment Glycobiology High 17621594 18025080
2007 Frontal affinity chromatography revealed that the carbohydrate recognition domain (CRD) of VIPL (LMAN2L) selectively interacts with deglucosylated trimannose in the D1 branch of high-mannose-type oligosaccharides in a Ca2+-dependent manner, with different pH dependence compared to VIP36. Structure-based mutagenesis showed that single amino acid substitutions in the CRD can switch the sugar-binding properties among L-type lectins. Frontal affinity chromatography with pyridylaminated sugar library, Ca2+-dependence assay, structure-based mutagenesis The Journal of biological chemistry High 18025080
2019 A frameshift mutation (c.1073delT) eliminating LMAN2L's ER retention signal causes mislocalization of the protein from the ER to the plasma membrane, establishing that the ER retention signal is required for proper subcellular localization and function in brain development. Genetic analysis of dominant mutation, protein localization assay demonstrating plasma membrane mistargeting Annals of clinical and translational neurology Medium 31020005
2024 HCMV pUS2 targets LMAN2L for proteasomal degradation via the host E3 ligase TRC8 through the ERAD pathway. LMAN2L loss results in downregulation of integrin alpha-6 (ITGA6) from the cell surface, demonstrating that LMAN2L is required for ITGA6 trafficking. Proteomics (plasma membrane profiling), genetic knockdown/overexpression of pUS2 and TRC8, co-immunoprecipitation The Journal of general virology Medium 38687323
2026 LMAN2L co-localizes and physically interacts with STING, and is essential for STING translocation from the ER to the Golgi upon activation. LMAN2L does not affect STING dimerization or TBK1 recruitment. HCMV pUS2 mediates LMAN2L degradation by recruiting the E3 ubiquitin ligase RNF139 and E2 ubiquitin-conjugating enzyme UBE2G2, directing LMAN2L through the ERAD pathway. LMAN2L knockout diminishes HCMV-induced type I interferon and ISG expression. Co-immunoprecipitation, co-localization (immunofluorescence), LMAN2L knockout with STING pathway readouts (IFN, ISG expression), ERAD pathway analysis with E3/E2 identification PLoS pathogens Medium 42149942

Source papers

Stage 0 corpus · 11 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 Molecular basis of sugar recognition by the human L-type lectins ERGIC-53, VIPL, and VIP36. The Journal of biological chemistry 121 18025080
2003 Profile-based data base scanning for animal L-type lectins and characterization of VIPL, a novel VIP36-like endoplasmic reticulum protein. The Journal of biological chemistry 59 12609988
2003 VIPL, a VIP36-like membrane protein with a putative function in the export of glycoproteins from the endoplasmic reticulum. Experimental cell research 50 12878160
2014 Genetic association of LMAN2L gene in schizophrenia and bipolar disorder and its interaction with ANK3 gene polymorphism. Progress in neuro-psychopharmacology & biological psychiatry 21 24914473
2007 VIPL has sugar-binding activity specific for high-mannose-type N-glycans, and glucosylation of the alpha1,2 mannotriosyl branch blocks its binding. Glycobiology 18 17621594
2015 Homozygous missense mutation in the LMAN2L gene segregates with intellectual disability in a large consanguineous Pakistani family. Journal of medical genetics 14 26566883
2020 Long Non-Coding RNA LINC00662 Regulated Proliferation and Migration by Targeting miR-34a-5p/LMAN2L Axis in Glioma. OncoTargets and therapy 12 33116598
2019 Dominant LMAN2L mutation causes intellectual disability with remitting epilepsy. Annals of clinical and translational neurology 10 31020005
2024 HCMV US2 co-opts TRC8 to degrade the endoplasmic reticulum-resident protein LMAN2L. The Journal of general virology 2 38687323
2026 HCMV-pUS2 Disrupts cGAS-STING Signaling through LMAN2L Degradation. PLoS pathogens 0 42149942
2025 Novel compound heterozygous mutations in LMAN2L cause early childhood refractory epilepsy. Italian journal of pediatrics 0 40221759

Missed literature

Know a paper Affinage missed for LMAN2L? Flag it for the maintainers and the community.

No submissions yet.